TCGA-B6-A0IN-01A-11R-A034-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 86
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.500
- ALLOGRAFT_REJECTION+0.420
- PANCREAS_BETA_CELLS+0.380
- COAGULATION+0.340
- KRAS_SIGNALING_UP+0.340
- COMPLEMENT+0.320
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.320
- MYOGENESIS+0.310
- OXIDATIVE_PHOSPHORYLATION+0.300
- XENOBIOTIC_METABOLISM+0.290
Top 10 suppressed
- E2F_TARGETS-0.430
- MITOTIC_SPINDLE-0.430
- G2M_CHECKPOINT-0.420
- INTERFERON_ALPHA_RESPONSE-0.390
- MYC_TARGETS_V2-0.320
- UNFOLDED_PROTEIN_RESPONSE-0.300
- MYC_TARGETS_V1-0.290
- WNT_BETA_CATENIN_SIGNALING-0.200
- UV_RESPONSE_DN-0.170
- ANDROGEN_RESPONSE-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0DS-01A-11R-A056-07 | — | B | 0.875 |
| 2 | SRR5088845 | — | — | 0.858 |
| 3 | TCGA-DK-A2I1-01A-11R-A180-07 | — | — | 0.849 |
| 4 | TCGA-21-5784-01A-01R-1635-07 | — | cohortSQ1 | 0.831 |
| 5 | TCGA-GM-A2DK-01A-21R-A180-07 | — | B | 0.812 |
| 6 | sclc2388_S39.txt | — | cohortMD2 | 0.806 |
| 7 | TCGA-97-8177-01A-11R-2287-07 | — | cohortA1 | 0.794 |
| 8 | TCGA-BH-A0HF-01A-11R-A056-07 | — | A | 0.791 |
| 9 | TCGA-AR-A2LJ-01A-12R-A19W-07 | — | B | 0.785 |
| 10 | BS_M4NVX721 | Ganglioglioma | — | 0.784 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.500 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.420 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.380 | Cobimetinib | — uncovered |
| COAGULATION | 0.340 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.340 | Inavolisib | — uncovered |
| COMPLEMENT | 0.320 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.320 | Inavolisib | — uncovered |
| MYOGENESIS | 0.310 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.290 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.280 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.240 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.240 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.230 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.220 | Inavolisib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.220 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.210 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |